Summit Therapeutics (SMMT) Stock Forecast & Price Target

Compare

1,689 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SMMT Analyst Ratings

Moderate Buy

11 Buy

1 Hold

3 Sell

Based on 15 analysts giving stock ratings to

Summit

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SMMT Stock 12 Month Forecast

Average Price Target

$29.25

▲(52.74% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Summit Therapeutics in the last 3 months. The average price target is $29.25 with a high forecast of $50.00 and a low forecast of $12.00. The average price target represents a 52.74% change from the last price of $19.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","21":"$21","31":"$31","41":"$41","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,21,31,41,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.84,25.852307692307694,27.864615384615384,29.876923076923077,31.88923076923077,33.901538461538465,35.91384615384615,37.926153846153845,39.93846153846154,41.95076923076923,43.963076923076926,45.97538461538461,47.98769230769231,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.84,24.256153846153847,24.672307692307694,25.088461538461537,25.504615384615384,25.92076923076923,26.336923076923078,26.75307692307692,27.16923076923077,27.585384615384616,28.001538461538463,28.417692307692306,28.833846153846153,{"y":29.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.84,22.92923076923077,22.018461538461537,21.107692307692307,20.196923076923078,19.286153846153844,18.375384615384615,17.464615384615385,16.553846153846152,15.643076923076922,14.732307692307693,13.821538461538461,12.91076923076923,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.67,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$29.25

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$13

Sell

-32.11%

Downside

Initiated

09/17/25

Summit Therapeutics (SMMT) Gets a Sell from Roth MKM

Etzer Darout

Barclays

$13

Sell

-32.11%

Downside

Initiated

09/16/25

Summit Therapeutics initiated with an Underweight at BarclaysSummit Therapeutics initiated with an Underweight at Barclays

Mitchell Kapoor

H.C. Wainwright

$50

Buy

161.10%

Upside

Reiterated

09/16/25

Summit Therapeutics' Ivonescimab Shows Promising Trial Results, Offering a Risk-Mitigation Opportunity with a Buy RatingWe reiterate our Buy rating and 12‐month price target of $50.

Daina Graybosch

Leerink Partners

$12

Sell

-37.34%

Downside

Reiterated

09/09/25

Leerink Partners Sticks to Its Sell Rating for Summit Therapeutics (SMMT)Reflecting KOL & management input – We reiterate UP with a $12 PT for Summit Therapeutics.

Cory Kasimov

Evercore ISI

$34

Buy

77.55%

Upside

Reiterated

09/08/25

Summit Therapeutics (SMMT) Gets a Buy from Evercore ISIWestern patients didn't show a significant progression-free survival benefit, with the EU arm underperforming in both PFS and OS. This discrepancy is concerning and needs further exploration. Additional Key takes: • FDA Discussions: SMMT might revisit talks with the FDA, but it's probably wiser to wait for the 1L lung trials to avoid starting the IRA clock prematurely.

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

09/08/25

TD Cowen Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

David Dai

UBS

$30

Buy

56.66%

Upside

Reiterated

09/08/25

Positive Buy Rating for Summit Therapeutics Driven by Promising HARMONi Trial Results and Anticipated Stock Upside

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

09/08/25

Truist Financial Remains a Buy on Summit Therapeutics (SMMT)

Reni Benjamin

Citizens JMP

$40

Buy

108.88%

Upside

Reiterated

09/08/25

Citizens JMP Remains a Buy on Summit Therapeutics (SMMT)Citizens JMP analyst Reni Benjamin reiterated a Market Outperform rating and $40.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).

Yigal Nochomovitz

Citi

$35

Buy

82.77%

Upside

Reiterated

09/07/25

Summit Therapeutics: Buy Rating Affirmed on Strong HARMONi Study Results and Strategic Positioning

Bradley Canino

Guggenheim

$40

Buy

108.88%

Upside

Initiated

09/03/25

Summit Therapeutics initiated with a Buy at GuggenheimSummit Therapeutics initiated with a Buy at Guggenheim

Mohit Bansal

Wells Fargo

$30

Buy

56.66%

Upside

Reiterated

08/28/25

Analysts Offer Insights on Healthcare Companies: Alector (NASDAQ: ALEC), Summit Therapeutics (NASDAQ: SMMT) and Cooper Co (NASDAQ: COO)

Kelsey Goodwin

Piper Sandler

$21

Hold

9.66%

Upside

Initiated

08/19/25

Summit Therapeutics initiated with a Neutral at Piper SandlerSummit Therapeutics initiated with a Neutral at Piper Sandler

William Maughan

Clear Street

$30→$33

Buy

72.32%

Upside

Reiterated

08/13/25

Summit Therapeutics price target raised to $33 from $30 at Clear StreetSummit Therapeutics price target raised to $33 from $30 at Clear Street

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Reiterated

07/28/25

Cantor Fitzgerald Remains a Buy on Summit Therapeutics (SMMT)Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Summit Therapeutics plc (NASDAQ: SMMT).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$13

Sell

-32.11%

Downside

Initiated

09/17/25

Summit Therapeutics (SMMT) Gets a Sell from Roth MKM

Etzer Darout

Barclays

$13

Sell

-32.11%

Downside

Initiated

09/16/25

Summit Therapeutics initiated with an Underweight at BarclaysSummit Therapeutics initiated with an Underweight at Barclays

Mitchell Kapoor

H.C. Wainwright

$50

Buy

161.10%

Upside

Reiterated

09/16/25

Summit Therapeutics' Ivonescimab Shows Promising Trial Results, Offering a Risk-Mitigation Opportunity with a Buy RatingWe reiterate our Buy rating and 12‐month price target of $50.

Daina Graybosch

Leerink Partners

$12

Sell

-37.34%

Downside

Reiterated

09/09/25

Leerink Partners Sticks to Its Sell Rating for Summit Therapeutics (SMMT)Reflecting KOL & management input – We reiterate UP with a $12 PT for Summit Therapeutics.

Cory Kasimov

Evercore ISI

$34

Buy

77.55%

Upside

Reiterated

09/08/25

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

09/08/25

TD Cowen Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

David Dai

UBS

$30

Buy

56.66%

Upside

Reiterated

09/08/25

Positive Buy Rating for Summit Therapeutics Driven by Promising HARMONi Trial Results and Anticipated Stock Upside

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

09/08/25

Truist Financial Remains a Buy on Summit Therapeutics (SMMT)

Reni Benjamin

Citizens JMP

$40

Buy

108.88%

Upside

Reiterated

09/08/25

Citizens JMP Remains a Buy on Summit Therapeutics (SMMT)Citizens JMP analyst Reni Benjamin reiterated a Market Outperform rating and $40.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).

Yigal Nochomovitz

Citi

$35

Buy

82.77%

Upside

Reiterated

09/07/25

Summit Therapeutics: Buy Rating Affirmed on Strong HARMONi Study Results and Strategic Positioning

Bradley Canino

Guggenheim

$40

Buy

108.88%

Upside

Initiated

09/03/25

Summit Therapeutics initiated with a Buy at GuggenheimSummit Therapeutics initiated with a Buy at Guggenheim

Mohit Bansal

Wells Fargo

$30

Buy

56.66%

Upside

Reiterated

08/28/25

Analysts Offer Insights on Healthcare Companies: Alector (NASDAQ: ALEC), Summit Therapeutics (NASDAQ: SMMT) and Cooper Co (NASDAQ: COO)

Kelsey Goodwin

Piper Sandler

$21

Hold

9.66%

Upside

Initiated

08/19/25

Summit Therapeutics initiated with a Neutral at Piper SandlerSummit Therapeutics initiated with a Neutral at Piper Sandler

William Maughan

Clear Street

$30→$33

Buy

72.32%

Upside

Reiterated

08/13/25

Summit Therapeutics price target raised to $33 from $30 at Clear StreetSummit Therapeutics price target raised to $33 from $30 at Clear Street

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Reiterated

07/28/25

Cantor Fitzgerald Remains a Buy on Summit Therapeutics (SMMT)Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Summit Therapeutics plc (NASDAQ: SMMT).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Summit Therapeutics

1 Month

xxx

Success Rate

6/9 ratings generated profit

Average Return

+7.07%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +7.07% per trade.

3 Months

xxx

Success Rate

6/6 ratings generated profit

Average Return

+22.63%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +22.63% per trade.

1 Year

Kelly ShiJefferies

Success Rate

4/6 ratings generated profit

Average Return

-1.18%

reiterated a buy rating 4 months ago

Copying Kelly Shi's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of -1.18% per trade.

2 Years

xxx

Success Rate

4/6 ratings generated profit

Average Return

-1.18%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of -1.18% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SMMT Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SMMT has received 25 Buy Ratings, 1 Hold Ratings, and 5 Sell Ratings. SMMT average Analyst price target in the past 3 months is 29.25.

Each month's total comprises the sum of three months' worth of ratings.

SMMT Financial Forecast

SMMT Earnings Forecast

Next quarter’s earnings estimate for SMMT is -$0.17 with a range of -$0.75 to -$0.08. The previous quarter’s EPS was -$0.76. SMMT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year SMMT has Outperformed its overall industry.

SMMT Sales Forecast

Next quarter’s sales forecast for SMMT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SMMT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.44% of the time in the same period. In the last calendar year SMMT has Preformed in-line its overall industry.

SMMT Stock Forecast FAQ

What is SMMT’s average 12-month price target, according to analysts?

Based on analyst ratings, Summit Therapeutics’s 12-month average price target is 29.25.

What is SMMT’s upside potential, based on the analysts’ average price target?

Summit Therapeutics has 52.74% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SMMT a Buy, Sell or Hold?

Summit Therapeutics has a consensus rating of Moderate Buy which is based on 11 buy ratings, 1 hold ratings and 3 sell ratings.

What is Summit Therapeutics’s price target?

The average price target for Summit Therapeutics is 29.25. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $12.00. The average price target represents 52.74% Increase from the current price of $19.15.

What do analysts say about Summit Therapeutics?

Summit Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of SMMT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Summit Therapeutics (SMMT) Stock Forecast & Price Target

SMMT Analyst Ratings

SMMT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Summit Therapeutics

SMMT Analyst Recommendation Trends

SMMT Financial Forecast

SMMT Earnings Forecast

SMMT Sales Forecast

SMMT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts